Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 15/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906230 | 0.95 | PDE3A (0.49) | PDGFRBPDE3APDGFRATLR9TLR7 | |
| SCHEMBL6700735 | 0.83 | PDGFRB (0.53) | KDM1APDGFRBKIT | |
| SCHEMBL6950156 | 0.80 | KDM1A (0.57) | KDM1APDGFRBPDE3AKITPDGFRA | |
| SCHEMBL1132415 | 0.79 | PDGFRB (0.51) | PDGFRBPDE3APDGFRA | |
| SCHEMBL906228 | 0.79 | PDGFRB (0.56) | PDGFRBKITTLR9TLR7 | |
| SCHEMBL906231 | 0.79 | PDE10A (0.46) | PDGFRBPDE3APDGFRA | |
| SCHEMBL6704570 | 0.76 | PDGFRB (0.79) | PDGFRBKITPDGFRA | |
| SCHEMBL6704362 | 0.76 | PDGFRB (0.79) | PDGFRBKITPDGFRA | |
| SCHEMBL906243 | 0.76 | KIT (0.59) | PDGFRBPDE3AKITPDGFRA | |
| SCHEMBL29055042 | 0.76 | PDE3A (0.57) | PDGFRBPDE3AKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259881-A1 | Nitrogenous heterocyclic compounds | KYOWA HAKKO KOGYO CO, LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1309567-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | Millennium Pharmaceuticals, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002016360-A2 | NITROGENOUS HETEROCYCLIC COMPOUNDS | COR THERAPEUTICS, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259881-A1 | Nitrogenous heterocyclic compounds | WNK2, CDK5, PDGFRA | KDM1A 4148/4885PDGFRB 5/4885PDE3A 753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.